Todo DSpace

Listar por tema "fluindostatin"

Mostrando ítems 1-3 de 3

    • Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 

      Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)
      Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...

    • Marketed drugs used for the management of hypercholesterolemia as anticancer armament 

      Papanagnou P., Stivarou T., Papageorgiou I., Papadopoulos G.E., Pappas A. (2017)
      The design of novel pharmacologic agents as well as their approval for sale in markets all over the world is a tedious and pricey process. Inevitably, oncologic patients commonly experience unwanted effects of new anticancer ...

    • On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells 

      Ntolkeras G., Barba C., Mavropoulos A., Vasileiadis G.K., Dardiotis E., Sakkas L.I., Hadjigeorgiou G., Bogdanos D.P. (2019)
      Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and ...